Skip to main content
Commercial newswire·DE·

フレン・ヘルス、次世代の創傷治療用組換え酵素の製造に、AGCバイオロジクスを選定

ハイデルベルク拠点が、第II相試験に向けたラクトペルオキシダーゼおよびグルコースオキシダーゼのGMP開発を主導 ハイデルベルク拠点が、第II相試験に向けたラクトペルオキシダーゼおよびグルコースオキシダーゼのGMP開発を主導

Short extract only — this publisher licenses its text. Read the full release at the source.

More from Commercial newswire

The rest of this wire is for subscribers

Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

7 days, no card required.

Read releases like this the second they cross the wire.

1,400+ feedslive on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.

PPN Source →
Shared via PPN World — real-time press release intelligence.